Cell-cycle kinetics were measured in situ after infusions of iododeoxyuridine and/or bromodeoxyuridine in 50 patients with myelodysplastic syndromes (MDS) and the median labeling index in bone marrow (BM) biopsy samples was 28.69/0. Unfortunately, 26 of 50 patients showed that ~7 5 4~ of hematopoietic cells of all three lineages were undergoing programmed cell death (PCD) in their biopsy samples as shown by the in situ end labeling (ISEL) technique. Ten patients had 1/3 and eight had 2/3 ISEL+ cells. Stromal cells were frequently ISEL' and often S-phase cells were also found to be simultaneously ISEL'. Nucleosomal DNA fragments as a ladder in agarose gel were present in BM aspi-HE MYELODYSPLASTIC syndromes (MDS) are a group of acquired hematopoietic disorders with evidence of trilineage dysplasia and an -30% incidence of eventual transformation into acute myeloid leukemia (AML).'-3 These are clonal disorders involving one or more cl0nes,4~ and normal hematopoiesis has been shown to simultaneously coexist in the majority of cases.6 Patients with evidence of "Abnormally Localized Immature Precursors" (ALIP) in their bone marrow (BM) biopsy samples tend to die earlier than ALIP-negative patients because of a rapid transformation into acute leukemia.' Cytogenetic abnormalities especially involving chromosomes 5 and 7 are commonly detected,K whereas ras-mutations signifying short survival have been showed in 010% to 40% patients.' The disease is almost invariably fatal, and with the exception of BM transplantation, there is no known cure."' An apparent paradox in MDS is that patients with these disorders have peripheral cytopenias despite frequently having normo-or hypercellular BMs. One possible explanation for this contradictory finding may be that even though there are large numbers of cells in the BM, they are not exiting that compartment because they are undergoing premature programmed cell death (PCD). To examine this possibility, the present study was undertaken to define the incidence of PCD in the hematopoietic cells of MDS patients. Apoptosis is a gene-directed cellular self-destruction in which intracel- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1995 by The American Society of Hematology. 0006-4971/95/8601-0026$3.00/0 268 rates of four patients who showed high ISEL and were absent in two who had no ISEL staining in biopsy samples, but only when DNA was extracted after a 4-hour in vitro incubation in complete medium. Therefore, laddering data confirmed the ISEL findings that the majority of hematopoietic cells in MDS are in early stages of PCD. We conclude that extensive intramedullary cell death may explain the paradox of pancytopenia despite hypercellular marrows in MDS patients. Investigating approaches that protect against PCD in some MDS subsets would be of interest.
rates of four patients who showed high ISEL and were absent in two who had no ISEL staining in biopsy samples, but only when DNA was extracted after a 4-hour in vitro incubation in complete medium. Therefore, laddering data confirmed the ISEL findings that the majority of hematopoietic cells in MDS are in early stages of PCD. We conclude that extensive intramedullary cell death may explain the paradox of pancytopenia despite hypercellular marrows in MDS patients. Investigating approaches that protect against PCD in some MDS subsets would be of interest.
0 1995 by The American Society of Hematology. lular endonucleases initially cleave the DNA into internucleosomal fragments (180 to 200 bp or their integral multiple~).""~ This process, which begins with fragmentation of DNA, ends eventually with fragmentation of the nucleus and removal of the dead cell by macrophages. Although an endstage karyorrhectic cell is easy to recognize under a light microscope, the earlier stages of PCD with limited DNA fragmentation and internucleosomal nicking cannot be morphologically identified. Thus, large numbers of cells may be undergoing apoptosis, yet there may be only a few cells in the morphologically identifiable karyorrhectic stage. Consequently, an accurate estimation of the incidence of PCD must include a precise quantitation of cells in early stages of apoptosis in addition to the obviously karyorrhectic cells. The conventional method of detecting typical "DNA laddering" by gel electrophoresis may not be able to provide this information because very little low molecular-weight DNA fragments are formed in cells that are in the earlier stages of PCD." The technique of in situ end labeling (ISEL) of fragmented DNA appears to be a more reliable measurement of the early stages of apoptosis.""' Therefore, BM biopsy samples of 50 MDS patients were processed for ISEL. The results obtained showed an exceptionally high rate of apoptosis in the hematopoietic cells of all three lineages in these patients. These data confirmed our initial hypothesis that high intramedullary death of hematopoietic cells may be the biologic basis for the paradox of pancytopenia despite hypercellular marrows in MDS patients.
MATERIALS AND METHODS
Rates of hematopoietic cellular proliferation and apoptosis were examined in fifty patients with a confirmed diagnosis of MDS. Each patient received a l-hour infusion of bromo-andor iododeoxyuridine (BrdU and IUdR) at 100 mg/m2 as per protocols MDS 86- 15 andor MDS 90-02. Informed consent was obtained from every individual. The infusion protocols were approved by the local Institutional Review Board and the Food and Drug Administration and the drugs were provided by the National Cancer Institute. Some of these patients' results have also been reported in earlier studies.2"22 Two methods were used to measure the rate of apoptosis in these patients. The in situ end labeling (ISEL) of fragmented DNA as described by Wijsman et all6 was modified for use in plastic embedded biopsy samples for the detection of cells undergoing PCD. BM asps from six MDS patients, three AML patients, and two normal controls were examined for the presence of the typical ladder pattern in agarose gels. Details of both methods are provided below.
ISEL of Fragmented DNA
Two-micrometer sections from the previously mentioned BM biopsy samples were obtained. The sections were rehydrated in distilled water for 10 minutes and then incubated with freshly diluted 3% hydrogen peroxide (H202) for 30 minutes. 
Control Experiments for ISEL Technique
controls: negative and positive.
Control experiments for ISEL technique included two types of

Negative Controls
ISEL solution devoid of DNA polymerase was used on control samples as negative controls. These slides were universally negative.
Positive Controls
Positive controls included DNA laddering versus ISEL of fragmented DNA, detection of apoptosis in BM biopsy samples obtained from newly diagnosed high-risk patients with AML, and detection of apoptosis in normal BM biopsy samples obtained from patients with non-Hodgkin's lymphoma (NHL).
DNA laddering versus ISEL of fragmented DNA. HL-60 cells were treated with a topoisomerase inhibitor etoposide (VP 16) at a concentration of 35 pmol/L/mL in RPM1 1640 medium containing 20% fetal bovine serum (FBS). The control cells were incubated in the same medium without etoposide. The incubation was continued for 4 hours at 37°C in 5% CO2. At the end of the incubation, each sample was divided into two aliquots. Cells from one aliquot were embedded in plastic, sectioned, and processed for ISEL to determine the percentage of apoptotic cells, whereas the other aliquot was used for DNA extraction. The DNA so obtained was run on an agarose gel containing ethidium bromide.
Detection of apoptosis in BM biopsy samples obtained from newly diagnosed high-risk patients with acute myeloid leukemia (AML). Twenty AML biopsy samples were processed for ISEL before starting remission induction chemotherapy.
Detection of apoptosis in normal BM biopsy samples obtained from patients with NHL. Two NHL patients who had no BM involvement and whose BM biopsy samples were judged by hematopathologists to be indistinguishable from normal BM biopsy samples were also processed for ISEL technique to determine the incidence of apoptotic cell death.
Interpretation of BM Biopsy Specimen Slide
All slides were examined under a light microscope attached to a television screen. At least three different investigators were involved in the interpretation of each slide (A.R. being one of them every time).
Proliferation Studies
Immunohistochemical detection of IUW-and/or BrdU-labeled Sphase cells was accomplished using either the anti-IUdRiBrdU MoAb 3D9 or the anti-BrdU MoAb Br-3. The nuclei of cells engaged in DNA synthesis were stained dark-brown in single-label slides. The labeling index (LI) was obtained by counting only the labeled myeloid cells as described
Frequently erythroid islands as well as occasional megakaryocytes were also in S-phase and these were easily recognizable because of their unique morphologic appearance. These labeled erythroid and megakaryocytic cells and their unlabeled counterparts were excluded from the L1 calculations. At least 2,000 cells from five different fields were counted.
PCD Studies by ISEL
Coverslips processed for ISEL were mounted onto glass slides and examined on the television screen by a group of observers (AR was always present). The slides were first scanned under low power. ISEL+ cells showed clear, punctate brown staining over their nuclei, often being most marked in the perinuclear area. Areas of apoptosis and PCD were identified if these were present in compartmentalized pockets. The following scoring system was used to approximately quantitate the incidence of PCD: absent, only an occasional ISEL' cell, definitely constituting 5 
Simultaneous Proliferation and PCD Studies
In these double-labeled slides, the nuclei of S-phase cells were stained blue, the nuclei of ISEL+ cells were stained brown and those S-phase cells that were also ISEL' showed the presence of both brown and blue staining.
Detection of DNA Laddering
Detection of DNA laddering was performed on BM asp cells of six MDS and three AML patients as well as two BM asp samples that were completely normal (obtained from BM transplant donors). After density separation on Ficoll-Hypaque, 1 X IO6 cells/mL were incubated for 4 hours at 37°C in 5% CO2 atmosphere and used for DNA extraction. Cells without the 4-hour incubation were also similarly used for DNA extraction. The reason for incubating cells over various time points before extracting DNA was as follows: Our hypothesis based on the ISEL data in BM biopsy samples was that most of the cells appeared to be in earlier stages of PCD with only low amounts of DNA damage that may not be sufficient to produce laddering in gels. However, leaving the cells in complete medium over specified time points may be enough time for the cells to complete the process of apoptosis with generation of low molecularweight DNA that would produce the typical DNA laddering. Thus, although initial experiments used a variety of time points (0, 1, 2, 3, and 4 hours) for in vitro incubation of cells in complete medium before DNA extraction, later experiments have used only the 0-and 4-hour time points because they appear to be the two most informative intervals.
Briefly, the cells were washed in 0.1 m o m PBS, pH 7.5 (0. I mol/ L NaCl in 0.1 mol/L PBS) to remove traces of medium, lysed with guanidine isothiocyanate (GITC) at room temperature and layered on 5.7 m o m cesium chloride (CsCI) gradient. After overnight centrifugation at 32,000 rpm, the DNA fraction at the interface of CsCl and GITC was aspirated and pooled together with the RNA fraction from the bottom of CsCl gradient tube. Subsequently, this preparation was treated with chilled 100% and 80% ethanol, incubated with Proteinase K (Boehringer Mannheim, Mannheim, Germany) and repeatedly treated with phenol:chloroform:isoamyl alcohol mixture (25:24:1, Sigma) to remove proteins. DNA was then precipitated by adding Na-acetate ( 3 mol/L, pH 6.0) and double volume of chilled 100% ethanol for 1 hour at -20°C. This DNA fraction was then treated with RNase concentration 1 pg/mL (final concentration 20 pg/mL) and subjected to reextraction using pheno1:chloroform:isoamyl alcohol mixture followed by treatment with Na-acetae and chilled 100% ethanol as described earlier. Finally, the total DNA content in each sample was estimated by optical density at 260 nm and 5 pg DNA was loaded in 1.5% agarose gel containing ethidium bromide. After electrophoresis, the gel was photographed under ultraviolet (UV) light.
Statistical Analysis
Mann Whitney tests were used for two sample comparisons of continuous variables. Contingency tables, with chi square statistics or Fisher's exact test, were used for analyzing.
RESULTS
Fifty patients with a confirmed diagnosis of MDS are the subject of this report. The French-American-British (FAB) classification was used to identify the various subtypes of MDS patients2' There were 19 cases of refractory anemia (RA), 6 cases of refractory anemia with ring sideroblasts (RARS), 17 cases of refractory anemia with excess blasts (RAEB), 7 cases of RAEB in transformation (RAEB-t) and 1 case of chronic myelomonocytic leukemia (CMMOL). BM cellularity was also available in all 50 cases. Table I describes the details of FAB type, apoptosis, cell cycle kinetics, biopsy sample cellularity and complete blood counts in all 50 patients.
Results of Control Experiments
A comparison of ISEL technique with DNA laddering detected by gel electrophoresis was performed on HL-60 cells treated with etoposide. Whereas untreated HL-60 cells did not show any low molecular-weight DNA, the cells treated with etoposide showed a characteristic DNA ladder pattern ( Fig 1A) . Results obtained by ISEL correlated very well with these data. The percentage of apoptotic (ISEL') cells in the control, untreated HL-60 cells was 1.59%. whereas this percentage in etoposide-treated HL-60 cells increased to 13.9% (Fig 1, B and C) . The DNA laddering and ISEL methods were similarly compared in at least three more sets of experiments and results obtained repeatedly showed that an accurate detection of apoptotic cells can be accomplished using either.
Once satisfied that ISEL is a highly accurate method of detecting PCD, we proceeded to use plastic embedded BM biopsy samples obtained from MDS patients for precise quantitation of apoptotic cell death.
Incidence of spontaneous apoptosis was quantitatively scored in 20 BM biopsy samples obtained from AML patients studied at the time of diagnosis and before receiving any remission induction chemotherapy. None of these biopsy samples showed greater than 10% to 15% of the total cells positive for ISEL staining. The leukemic blasts were universally negative. The few ISEL+ cells were usually present in small clusters and appeared morphologically to represent areas of residual normal hematopoiesis. Furthermore, double-labeling showed that none of the S-phase cells were ISEL'.
PCD was also studied in two normal BM biopsy samples obtained from NHL patients. Both the patients showed geographically well-defined areas of apoptotic cell death scattered throughout the samples. Within these ''geographically restricted islands of death," all three lineages of cells were ISEL', as were occasional stromal cells. On the whole, such areas accounted for approximately one third of the BM biopsy sample area, but it was never as extensive as in MDS patients. Finally, S-phase cells were never double-labeled for ISEL in these samples.
Proliferation Studies
Sequential labeling of S-phase cells was performed in vivo using infusions of IUdR and/or BrdU. Labeling indices (LI) from BM biopsy samples were available in 46 patients. The median L1 was 28.6% with a range of 13% to 49.1%. Dura- tion of S-phase (Ts) was available in 30 patients with a median of 12.8 hours and a range of 3.0 to 65.8 hours. Total cell cycle time (Tc) was available in 29 with a median of 40.0 hours (range, 9.1 to 224.6 hours). These data are also provided in Table 1 for individual patients.
Apoptosis Studies
In situ end labeling of fragmented DNA was performed on the plastic embedded biopsy samples of all 50 patients.
A distinct brown staining in a variety of patterns over the nucleus identifies a cell as being engaged in DNA cleavage. Among the 50 cases being reported, one biopsy sample was excluded because of poor quality of the sample whereas four cases showed "absent" apoptosis or only occasional ISEL+ cells and were considered as ISEL-( cluding the myeloid, erythroid and megakaryocytic cells were found to be undergoing apoptosis. Figure 2 shows some of these ISEL' cells. Furthermore, almost in every case, stromal cells were also found to be apoptotic including endothelial cells, fat cells, and fibroblasts. In Figure 2 , ISEL' as well as negative fibroblasts and endothelial cells can be seen. Figure 3 shows the typical crescent-shaped chromatin condensation in an AML patient's leukemic blast as stained by the ISEL technique.
Simultaneous Labeling for Proliferation and Apoptosis
Double labeling using ISEL and anti-IUdRBrdU antibody techniques was performed on 15 MDS patients. In every case, S-phase cells were frequently found to be undergoing apoptosis as well. Figure 4 clearly shows a megakaryocyte that is synthesizing DNA (blue staining) and is also undergoing apoptosis (brown staining) or is in a state of "Antonymy." Because all of the first 15 consecutive patients examined by this doublelabeling technique showed the same concurrent cell-birthkelldeath pattern, the remaining biopsy samples were not doublelabeled. In a number of patients, macrophages filled with ISEL+ debris of apoptotic cells were recognizable (Fig 5) . Figure 6 shows the results in these 11 individuals. Lane 1 shows the DNA molecular marker, (100-bp DNA ladder). The next two lanes show the results in 2 normal donors whose BM asps were incubated for 4 hours in complete medium before extraction of DNA. No evidence of DNA laddering can be seen in either of the normal samples. Similarly, the next four lanes show three AML patients and none of them show any DNA laddering either. On the other hand, lanes 8 through 18 represent 0-and 4-hour samples of six MDS patients. The first four of these (Table 1, 
Results of DNA Laddering in MDS,
Other Clinical and Biologic Characteristics Versus Proliferation and Apoptosis
The rates of cell birth and cell death were compared in the various FAB categories. Apoptosis was maximum in RAEB-t patients, all 7 having greater than 50% ISEL' cells, whereas 9 RA patients had high and 9 had low ISEL-positivity ( P = .057) with two patients having intermediate positivity. Most importantly, even though there was so much cell death in RAEB-t patients, clusters of ISEL-myeloblasts (ALIPs) were clearly recognizable. On the other hand, L1 was below median for 5 of 7 RAEB-t patients, whereas half the RA patients had above and half had below median LI. ISEL results were also corelated with other parameters such as L1 ( P = .314), Ts ( P = .234), Tc ( P = .275), WBC ( P = .160), Hb ( P = .801), platelets ( P = .273), and biopsy sample cellularity ( P = .648). No statistically significant relationships were identified.
DISCUSSION
A recently described technique for detecting PCD that uses ISEL of fragmented has been used in the present study to determine the incidence of intramedullary cell death in patients with myelodysplastic syndromes. Four unique observations have been made in the present study. First, that myelodysplastic syndromes are highly proliferative disorders with almost one third of the marrow cells engaged in DNA synthesis (median L1 for myeloid cells, 29%; median cell cycle time, 44 hours). Second, that unfortunately this high rate of cell birth is cancelled by an equally high rate of cell-death resulting in a functionally aplastic BM, an observation that constitutes the most likely basis for the apparent paradox of pancytopenia despite hypercellular marrows encountered in the majority of these patients. This high rate of apoptosis affected not only all three lineages of the hematopoietic cells, but also involved cells of stromal origin (fat cells, endothelial cells, fibroblasts).
Third, that many cells are simultaneously engaged in DNA synthesis and apoptosis. Fourth, that the DNA extracted immediately upon density separation of BM asps showed no laddering in agarose gels, whereas DNA extracted after a 4-hour incubation of density-separated cells in complete medium showed the characteristic laddering in 4 of 4 MDS patients with 250% ISEL' cells in the matched biopsy samples, but none in the 2 of 2 MDS patients with no ISEL staining in their biopsy samples. While a high rate of apoptosis has previously been hypothesized to be a possible explanation for the ineffective hematopoiesis observed in these disorders on the basis of finding increased apoptotic nuclei in trephine sections,'" the present report is the first documented proof that large numbers of marrow cells are engaged in earlier stages of PCD. Several features of this study are unexpected. To begin with, the extent of apoptosis encountered was previously unsuspected.
In 26 of 50 patients examined, there was evidence that 275% of all hematopoietic cells were apoptotic. Second, the death of surrounding stromal cells came as a surprise. There could be a variety of reasons for the simultaneous death of stromal and parenchymal cells. Because MDS is a clonal disease, the leukemia cells may be producing noxious factors that poison the BM microenvironment, which then becomes equally toxic for stroma and parenchyma. Conversely, the lesion in MDS may be in a pluripotential stem cell, which is the parent for both stromal and parenchymal cells, although the actual existence of such a cell has not been shown to date. Finally, the BM microenvironment may be diseased itself so that it is unable to support the growth of most stromal/parenchymal cells.
Finding the highest rate of apoptosis in RAEB-t patients was also unexpected. The important thing to remember here is that it was the differentiated cells which were apoptotic. The clearly leukemic blasts that were found most commonly in ALIP clusters were quite negative for apoptosis. If one considers MDS as a disease that evolves from RA to RAEB-t, then it is not surprising that the rate of cell death is maximum for RAEB-t patients. This observation appears to implicate the leukemia clone (which is numerically the largest in RAEB-t) as the culprit for producing factors that induce apoptosis in surrounding cells. Final proof regarding the lineage of morphologically differentiated cells that are apoptotic must await until better techniques are developed to mark normal versus leukemic cells in BM biopsy samples.
Finally, direct and visually striking proof that cells actively synthesizing DNA may also be simultaneously traversing the path to PCD was not predicted. It is possible to hypothesize that such cells have retained some DNA damage during the replication process that initiates the signaling for a state of quiescence (possibly via an intact p53 pathway). This simultaneous engagement of a cell in incompatible and mutually contradictory pathways of proliferation and quiescence has been termed "antonymy" by Hibner and Coutinho" and shown to ultimately result in the apoptotic death of the cell. Because recent evidence has accumulated to show a shortening of telomeres in MDS patients, hypotheses such its the one presented above are not purely conjectural.32 DNA laddering data obtained from the BM asps of 1 I individuals are particularly interesting. No apoptosis or laddering was observed in the six MDS patients, two normal individuals who were BM transplant donors or the three AML patients when DNA was extracted immediately from their density-separated BM asps (0-hour samples). Based upon our observations of ISEL-staining in BM biopsy samples, our hypothesis was that most of the cells appeared to be in early stages of PCD in MDS patients so that there may not be enough low molecular-weight DNA to produce the characteristic laddering on agarose gels. Therefore, finding no laddering in the MDS patients at 0 hours confirmed this hypothesis. We next allowed density-separated cells to sit in complete medium for various time points (1, 2, 3, and 4 hours) before extracting DNA from them to allow for completion of the apoptotic process in vitro. As expected, we began to see some laddering at 3 hours and by 4 hours, there was evidence of laddering in all four MDS patients whose biopsy samples showed ISEL-staining in 250% cells. No laddering was observed in the 0-hour or any of the later time points in two MDS patients who had no ISEL-staining in their biopsy samples. The three AML and two normal controls had no laddering either at 0 or 4 hours. These data further confirm our findings that large numbers of hematopoietic cells in MDS patients are engaged in early stages of PCD.
The obvious questions to be asked now relate to the clinical relevance of these observations. Clearly, if the lesion in MDS is a high apoptotic death of hematopoietic cells, then attempts should be made to determine the potential cause (or causes) for this mass suicide. Although the details are beyond the scope of this paper, we have already shown unexpectedly high levels of tumor necrosis factor alpha (TNFa) and transforming growth factor /? in the BM biopsy samples of these patient^.^'.'^ Obviously, if the basis for ineffective hematopoiesis is premature intramedullary death of hematopoietic cells, then attempts should be undertaken to suppress apoptosis in MDS patients. We are presently conducting a clinical trial to examine the role of pentoxifylline in restoring normal longevity to these cells by downregulating the production of TNFa in these patients.?' It must be remembered that reducing the incidence of apoptosis in more differentiated cells may normalize the peripheral blood counts and reverse the pancytopenia, but will probably not have any effect on the leukemic clone already present in these patients. Thus, for RA and RARS patients, this may be a treatment of choice, but RAEB and RAEB-t patients for whom the leukemic cell mass is already rather substantial would probably require a two-pronged approach. Alternating cycles of chemotherapy to kill leukemic clonal cells versus biotherapy to suppress apoptosis in the differentiating (normal) cells may be more desirable for patients with excess of blasts.
Finally, the question of increased proliferation needs to be addressed in MDS. Our hypothesis is that the primary lesion in MDS is a high cell-death rate and the increased cell birth is the body's compensatory mechanism to neutralize this lesion. We hypothesize further that once the cells are allowed to live their normal life-span by suppression of apoptosis, we should witness a reduction in the proliferation rate towards normal. The clinical studies are not mature enough to test this hypothesis.
One clear avenue for future biologic research in MDS that must be pursued immediately is to develop the ability to distinguish between normal and leukemic (clonal) cells in the BM biopsy samples of these patients. For those individuals who have numerical karyotypic abnormalities such as trisomy 8 or monosomy 7, we are attempting to answer this critical question by performing interphase cytogenetics in plastic embedded BM biopsy samples. Furthermore, we are developing immunohistochemical methods to detect CD34+ versus negative cells using a MoAb. Once the latter is achieved, double-labeling for ISEL and CD34 status will be highly informative.
